Pennsylvania 2025-2026 Regular Session

Pennsylvania House Bill HB719

Introduced
2/24/25  

Caption

Prohibiting discriminatory practices against applicants and enrollees under certain insurance policies based on claims or prescriptions involving prophylaxis HIV medication.

Summary

HB719 would prohibit insurers from taking adverse actions against an applicant or enrollee solely because that person has filled or been prescribed HIV prophylaxis medication, specifically PrEP (pre-exposure prophylaxis) or PEP (post-exposure prophylaxis). The bill defines adverse actions to include denying or canceling coverage, limiting coverage, or charging a different rate based only on a claim or prescription for these medications. The measure applies to life insurance, disability insurance, long-term care insurance, and related subscriber contracts, certificates, or plans offered by insurers regulated under Pennsylvania insurance law. It creates a short title, the "Prohibiting Insurance Discrimination for Persons on PrEP and PEP Act," and takes effect 60 days after enactment.

Impact

The bill would amend the practical operation of Pennsylvania insurance law by making discrimination based solely on PrEP or PEP use an enforceable violation of existing insurance standards. Specifically, such conduct would be treated as unfair discrimination under the Insurance Company Law of 1921 and as an unfair method of competition and unfair or deceptive act or practice under the Unfair Insurance Practices Act, giving regulators a basis to investigate and penalize insurers that use HIV prophylaxis prescriptions as a rating or underwriting factor.

Sentiment

No committee transcript or vote record is available, so there is no direct evidence of debate or recorded support/opposition in the materials provided. Based on the bill text and its introduction by multiple sponsors, the measure appears to be framed as a consumer-protection and anti-discrimination bill aimed at ensuring access to insurance without stigma tied to HIV prevention medication use.

Contention

The main point of potential contention is whether insurers should be barred from considering PrEP or PEP use at all in underwriting or pricing decisions. Supporters would likely view the bill as preventing unfair stigma and protecting access to preventive healthcare, while opponents may argue it restricts actuarial underwriting practices or could affect risk assessment in life, disability, or long-term care insurance. The bill text itself resolves that dispute in favor of a categorical prohibition when the medication use is the sole basis for the adverse action.

Companion Bills

No companion bills found.

Previously Filed As

PA HB1301

Requiring health insurance policies to provide coverage for pre-exposure prophylaxis and post-exposure prophylaxis HIV medication and associated laboratory tests and patient visits.

PA HB111

Prohibiting discrimination in certain life insurance policies based on certain drugs.

PA SB935

Requiring health insurance policies to provide coverage for preexposure prophylaxis HIV medication.

PA SB936

Requiring health insurance policies to provide coverage for postexposure prophylaxis HIV medication.

PA A3675

Authorizes pharmacists to dispense HIV prophylaxis without individual prescription under certain circumstances; mandates prescription benefits coverage.

PA S2586

Authorizes pharmacists to dispense HIV prophylaxis without individual prescription under certain circumstances; mandates prescription benefits coverage.

PA SB195

Pharmacies; pharmacists are authorized to dispense preexposure prophylaxis and postexposure prophylaxis under certain conditions; provide

PA S1638

Prohibitions Against Discriminatory Practices Relating to 340B Entities and 340B Drugs

PA H1527

Prohibitions Against Discriminatory Practices Relating to 340B Entities and 340B Drugs

PA HB1527

Prohibitions Against Discriminatory Practices Relating to 340B Entities and 340B Drugs:

Similar Bills

No similar bills found.